Bank of New York Mellon Corp Has $1.30 Million Stock Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Bank of New York Mellon Corp lifted its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 271.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 82,006 shares of the company’s stock after buying an additional 59,930 shares during the period. Bank of New York Mellon Corp’s holdings in Dr. Reddy’s Laboratories were worth $1,295,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Robeco Institutional Asset Management B.V. grew its stake in Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after buying an additional 9,373,412 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Dr. Reddy’s Laboratories by 400.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after buying an additional 427,573 shares during the last quarter. Rhumbline Advisers grew its position in Dr. Reddy’s Laboratories by 458.0% in the 4th quarter. Rhumbline Advisers now owns 430,062 shares of the company’s stock worth $6,791,000 after purchasing an additional 352,994 shares during the last quarter. Artemis Investment Management LLP increased its holdings in shares of Dr. Reddy’s Laboratories by 398.3% during the 4th quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock worth $4,666,000 after purchasing an additional 236,224 shares during the period. Finally, Augustine Asset Management Inc. increased its holdings in shares of Dr. Reddy’s Laboratories by 392.6% during the 4th quarter. Augustine Asset Management Inc. now owns 249,744 shares of the company’s stock worth $3,943,000 after purchasing an additional 199,044 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

Shares of Dr. Reddy’s Laboratories stock opened at $13.73 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The firm’s 50-day simple moving average is $13.66 and its 200-day simple moving average is $14.68. Dr. Reddy’s Laboratories Limited has a twelve month low of $12.50 and a twelve month high of $16.89. The firm has a market cap of $11.46 billion, a P/E ratio of 21.86 and a beta of 0.48.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RDY. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.